LUM and neoplasm: Pro-IL-12 [17], IL-12-MSA-Lumican [19], CBD-IL-12 [20], M-L-IL-12 [18], and NHS-muIL12 [23]—designed based on fusion extracellular matrix or immune molecular strategies—showed good antitumor effects in preclinical tumor-bearing mice and had synergistic effects in combination with other therapies.